Debiopharm Partners with Alkyon to Advance Targeted Radioligand Therapies

• Debiopharm and Alkyon Therapeutics have entered a co-research agreement to explore targeted radioligand therapies (RLTs) using proprietary antibody and conjugation platforms.

• The partnership will assess the feasibility of combining Debiopharm’s AbYlink™ conjugation technology with Alkyon’s modular antibody scaffolds against undisclosed tumour-associated antigens.

Debiopharm, a Swiss biopharmaceutical company, has signed a co-research agreement with US-based Alkyon Therapeutics to evaluate the development of precision-targeted radioligand therapies (RLTs). The collaboration will combine Debiopharm’s proprietary AbYlink™ conjugation technology with Alkyon’s modular antibody platform targeting undisclosed tumour-associated antigens.

The research partnership aims to create a new class of RLTs that deliver radiation selectively to cancer cells while sparing healthy tissue. AbYlink™, which enables regio-selective lysine conjugation, is designed to avoid interfering with the target binding site, potentially offering more predictable and scalable manufacturing outcomes.

According to the press release, both companies are aligning their strengths to address treatment-resistant cancers. The initiative is intended to improve tolerability and therapeutic precision for patients with solid tumours.

“We’re intrigued to explore the potential of applying AbYlink™ conjugation technology to the radio-oncology field,” said Frederic Levy, Chief Scientific Officer at Debiopharm.

No financial terms or timelines for the agreement were disclosed. The companies plan to jointly assess the feasibility of this approach as a foundation for future clinical development.